Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovetumab + Chemotherapy in Advanced Squamous NSCLC
NCT01268059Phase 2Terminated
- Sponsor
- MedImmune
- Start
- Dec 2010
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of Tovetumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Dec 2010; status: terminated.
02
Drugs
Tovetumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01268059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01268059.